Compare Illumina, Inc. (ILMN) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Shell PLC — how do they compare? Illumina, Inc. trades at $191.6 (market cap $27.94B), while Shell PLC trades at $87 (market cap $235.24B). The key difference: Shell PLC is far larger — about 8.4× Illumina, Inc.'s market cap, and Shell PLC pays a 3.63% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | SHEL | |
|---|---|---|
Market Cap | $27.94B | $235.24B |
Sector | Health | Energy |
52-Week High | $194.33 | $94.15 |
52-Week Low | $91.00 | $70.31 |
Enterprise Value | $29.33B | $287.77B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Shell (SHEL) trades at $86.20, down 1.28% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company maintains solid fundamentals with a P/E of 13.6 and net income margin of 7.01%, though revenue has declined from $381.3B in 2022 to $266.9B in 2025. Recent developments include expansion in Caribbean LNG infrastructure and the pending $16.4B acquisition of ARC Resources, positioning for strategic growth despite Middle East production disruptions.
Outlook remains positive with analyst consensus at Buy (69%) and $114.13 price target, representing 32% upside. Key risks include geopolitical volatility affecting oil prices and ongoing production challenges. The stock offers value through discounted valuation metrics and dividend yield, though investors should monitor execution on growth initiatives and energy market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
